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Insulin and insulin-like growth factors I and II are closely
related protein hormones. Their distinct evolution has resulted
in different yet overlapping biological functions with insulin
becoming a key regulator of metabolism, whereas insulin-like
growth factors (IGF)-I/II are major growth factors. Insulin and
IGFs cross-bind with different affinities to closely related insu-
lin receptor isoforms A and B (IR-A and IR-B) and insulin-like
growth factor type I receptor (IGF-1R). Identification of struc-
tural determinants in IGFs and insulin that trigger their specific
signaling pathways is of increasing importance in designing
receptor-specific analogs with potential therapeutic applica-
tions. Here, we developed a straightforward protocol for pro-
duction of recombinant IGF-II and prepared six IGF-II analogs
with IGF-I-like mutations. All modified molecules exhibit sig-
nificantly reduced affinity toward IR-A, particularly the analogs
with a Pro-Gln insertion in the C-domain. Moreover, one of the
analogs has enhanced binding affinity for IGF-1R due to a syn-
ergistic effect of the Pro-Gln insertion and S29N point muta-
tion. Consequently, this analog has almost a 10-fold higher IGF-
1R/IR-A binding specificity in comparison with native IGF-II.
The established IGF-II purification protocol allowed for cost-
effective isotope labeling required for a detailedNMRstructural
characterization of IGF-II analogs that revealed a link between
the altered binding behavior of selected analogs and conforma-
tional rearrangement of their C-domains.
The insulin-insulin-like growth factor (IGF)4 axis is a com-
plex signaling pathway mediated by a group of three sequen-
tially and structurally homologous peptide hormones, their
membrane receptors, and several circulating IGF-binding pro-
teins. Insulin and IGF-I and -II are all capable of higher or lower
affinity binding toward the transmembrane tyrosine kinase
receptors insulin receptor isoform A (IR-A), insulin receptor
isoform B (IR-B), and insulin-like growth factor type I receptor
(IGF-1R) (1, 2). All three receptors also share a high degree of
homology, which is manifested by overlapping biological
responses upon ligand binding (3–5). Binding of insulin and
IGFs to the receptors triggers twomajor signaling pathways via
autophosphorylation of tyrosines within their intracellular
tyrosine kinase domains. The first, usually referred to as a phos-
phoinositide 3-kinase (PI3K)/Akt pathway, is key for the meta-
bolic effects of ligand binding such as a decrease in plasma
glucose levels (6). The second signaling pathway, referred to as
Ras/ERK, involves activation of the Ras/Raf/MAPK/ERK1/2
cascade, which mediates proliferative effects through gene
transcription regulation (7). Whereas insulin signals mainly
via both IR isoforms (8), IGF-I and IGF-II promote the mito-
genic signaling through IGF-1R (9, 10), and similar mito-
genic stimulation results from IGF-II binding to IR-A (11).
Both IGFs are essential for embryonic development and are
present in serum at nanomolar concentrations in adults (12)
with IGF-II levels being 3-fold higher than IGF-I levels (13).
Whereas the role of IGF-II in tumor development is well doc-
* This work was supported by Czech Science Foundation Grant 15-19018S,
Medical Research Council Grant MR/K000179/1, Ministry of Education of
the Czech Republic Programs “NAVRAT” LK11205 and “NPU I” LO1304,
Charles University Grant Agency Grant 227020, Specific University
Research (Ministry of Education of the Czech Republic Grant 20/2013,
A1_FCHI_2014_003), and Research Project of the Academy of Sciences of
the Czech Republic RVO:61388963. The authors declare that they have no
conflicts of interest with the contents of this article.
Author’s Choice—Final version free via Creative Commons CC-BY license.
□S This article contains supplemental Figs. S1–S8 and Table S1.
The atomic coordinates and structure factors (codes 5L3L, 5L3M, and 5L3N) have
been deposited in the Protein Data Bank (http://wwpdb.org/).
Theassignedchemical shiftshavebeendeposited into theBioMagResBankunder
accession numbers 34000, 34001, and 34002.
1 Joint first authors.
2 Towhomcorrespondencemay be addressed. Tel.: 420-220-183-135; E-mail:
vaclav.veverka@uochb.cas.cz.
3 To whom correspondence may be addressed: Inst. of Organic Chemistry
and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flem-
ingovo nám 2, 166 10 Prague 6, Czech Republic. Tel.: 420-220-183-441;
E-mail: zakova@uochb.cas.cz.
4 The abbreviations used are: IGF, insulin-like growth factor; IR, insulin recep-
tor; IR-A, insulin receptor isoformA; IR-B, insulin receptor isoformB; IGF-1R,
insulin-like growth factor type I receptor; IGF-2R, insulin-like growth factor
type II receptor; L1, leucine-rich repeat region; -CT, C-terminal helix; GB1,
immunoglobulin binding domain B1 of streptococcal Protein-G; TEV,
tobacco etch virus; RP-HPLC, reversed phase HPLC; HSQC, heteronuclear
single quantum coherence; D11, Domain 11; HMQC, heteronuclear multi-
ple quantum coherence.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 291, NO. 40, pp. 21234–21245, September 30, 2016
Author’s Choice © 2016 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
crossmark
21234 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 40•SEPTEMBER 30, 2016
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of Bristol Library Services on O
ctober 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
umented (14), its physiological role remains unclear. It is
known that IGF-II is important for fetal development and pla-
cental function (15, 16), and several animal studies indicate an
important role for IGF-II in memory enhancement (17–19).
The availability of IGF ligands for signaling is modulated by a
family of high affinity IGF-binding proteins 1–6 (20, 21) and
insulin-like growth factor type II receptor (IGF-2R) (22). The
equilibrium of individual components and the appropriate
function of the entire insulin-IGF system are essential for bio-
logical responses such as regulation of basal metabolism, cellu-
lar growth, proliferation, survival, and migration (23).
IGF-I and IGF-II are single chain peptides composed of 70
and 67 amino acids, respectively. Mature IGFs consist of four
domains: B, C, A, and D in order from the N terminus. IGF-I
and -II share over 60% sequence identity, mostly in the B- and
A-domains that correspond to the B and A chains in insulin
(Fig. 1). The 3D structure of IGF-I was obtained by both NMR
and x-ray (24–34), whereas the structure of IGF-II has been
determined only by NMR (35, 36). Together with insulin, these
hormones share the insulin-like conformation consisting of
three highly conserved -helices (Fig. 1) further stabilized by
three characteristic disulfide bonds (28, 36, 37).
IR-A, IR-B, and IGF-1R are homodimeric, and each mono-
mer consists of an extracellular subunit () and transmembrane
subunit () that are linked via four disulfide bonds into a func-
tional---homodimer (38–40). The alternative splicing of
IR exon 11 generates a 12-amino acid sequence in the C termi-
nus of the -subunit or IR-B that is absent in IR-A (41–43).
Each monomer contains two insulin/IGF binding sites termed
the primary (1) and second (2) site on onemonomer and 1 and
2 on the partner. The primary binding site is formed from a
leucine-rich repeat region (L1) and C-terminal helix (-CT)
region that combine with the second site of the partner mono-
mer (2) to form the complete binding pocket. The two sites
(1-2) bind a single molecule of insulin/IGF, triggering struc-
tural rearrangements and negative cooperativity for binding at
the 1-2 site (44–46). The mechanisms of insulin or IGF bind-
ing to their cognate receptors were originally proposed on the
basis of extensive mutagenesis studies only (47, 48). More
recently, however, several reports based on the crystal struc-
tures of the insulinIR complexes (49, 50), “activated” insulin
analogs (51–53), and the first bound structure of IGF-I through
complexation with a IR/IGF-1R hybrid construct (54) have
revealed the binding mode of the hormones at the receptor site
1 represented by the L1 subunit and -CT segment. However,
details of the precise arrangement of the C-domain of bound
IGF-I are currently unknown, but structural rearrangement of
this region in conjunction with the -CT region has been pro-
posed to be necessary to prevent unfavorable steric clashes.
Moreover, the C-domain is a region with major differences
between IGFs, both in the amino acid composition and length
(Fig. 1), probably being a key determinant of receptor binding
specificity.
Both insulin and IGF-I have been extensively studied
through the preparation and functional analysis of numer-
ous analogs (for extensive reviews, see Refs. 46, 48, and 55),
whereas the structure-function of IGF-II is less developed
(15, 56–62). To gain greater insight into the structural basis
of IGF-II binding specificity to IR-A and IGF-1R, we gener-
ated a series of mutants containing amino acid substitutions
within the B- and C-domains of IGF-II. These were designed
to make IGF-II more IGF-I-like (Fig. 1) and were tested
through binding affinities to their cognate receptors. This
was enabled by the development of a new, efficient, and cost-
effective protocol for recombinant production of IGF-II ana-
logs in sufficient quantities for structural characterization by
NMR. Our data revealed that the newly prepared IGF-II ana-
logs display conserved or slightly increased IGF-1R affinities
FIGURE1.A, theaminoacidsequencealignmentof insulin, IGF-I, and IGF-II. It illustrates theirhighprimarystructurehomologywiththeconservedresidueshighlighted
in dark gray and the residues conserved between IGF-I and IGF-II in light gray. The organization of IGF-I and IGF-II into B-, C-, A-, and D-domains is shown below the
sequences;domainsAandBcorrespondto insulinAandBchains.Thepositionsofconserved-helicesareshownasbarsabovethesequences. IGF-II residuesmutated
in this study are labeledwith an asterisk. B, the amino acid sequence of the six prepared IGF-II analogswith highlightedmutations.
Receptor Specificity of IGF-II Analogs
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but markedly reduced IR-A affinities, which correlates with
the specific conformational changes in the structurally elu-
sive C-domain of IGF-II.
Results
Recombinant Production of IGF-II—A prerequisite for this
study was the efficient production of correctly folded IGF-II,
which would serve as a reference molecule as well as a platform
for the design and production of new IGF-II analogs. This was
achieved by recombinant IGF-II expression in Escherichia coli
as a fusion with an N-terminal and cleavable His6-tagged GB1
protein (immunoglobulin binding domain B1 of streptococcal
Protein-G) (63, 64). This technique provided high yields (0.8–
1.8 mg liter1 of culture) of IGF-II analogs with only a single
additional glycine residue cloning artifact at the N terminus.
The fusion protein was successfully expressed in E. coli and
purified using immobilized metal ion affinity chromatography
(supplemental Fig. S1). Two major peaks were observed; the
first eluted at lower concentrations of imidazole (110–160mM;
fractions 1–2 in supplemental Fig. S1) and consisted of folded
and misfolded monomeric IGF-II with slightly different migra-
tion of two bands observable in non-reducing SDS-PAGE
(supplemental Fig. S1). The second peak eluted at higher con-
centrations of imidazole and consisted of multimeric forms
(310–480 mM; fractions 4–5 in supplemental Fig. S1). Both
monomeric and multimeric fusion proteins were subsequently
cleaved using TEV protease under redox conditions of oxidized
and reduced glutathione. Interestingly, the moderate reducing
environment triggered disulfide bond reshuffling that resulted in
liberation of monomeric IGF-II frommultimeric aggregates. Fol-
lowing cleavage, IGF-II was separated from the His6-tagged GB1
and TEV by immobilized metal ion affinity chromatography. RP-
HPLC of this crude IGF-II product consisted of one major peak
and two to fourminor peaks (supplemental Fig. S1). The retention
time of the major protein peak was nearly identical to that
observed for native human IGF-II, and the correct molecular
weight of the recombinantly produced purified IGF-II protein
with formed disulfide bonds was confirmed by high resolution
mass spectrometry. Both forms, monomeric and multimeric,
yielded the desired product of correct mass and were combined
after the correct protein fold was confirmed by 1D 1H NMR
(supplemental Fig. S2) and 1H-15N HSQC that was highly similar
to the previously published data (65).
In total, six IGF-II analogs were designed to determine the
effects of IGF-I motif incorporation into IGF-II. The modifica-
tions were as follows: (i) a point mutation at position Ser29 for
Asn ([N29]IGF-II), (ii) an insertion of Gly-Ser after Arg34
([R34_GS]IGF-II), (iii) an insertion of Pro-Gln after Ser39
([S39_PQ]IGF-II), (iv) a combination of both insertions
([R34_GS,S39_PQ]IGF-II), (v) a combination of S29N muta-
tion with Pro-Gln insertion ([N29,S39_PQ]IGF-II), and (vi)
a combination of S29N mutation with both insertions
([N29,R34_GS,S39_PQ]IGF-II). All analogs gave comparable
RP-HPLC elution profiles (data not shown) with that of IGF-II
(supplemental Fig. S1) with one major product and several
minor peaks. The characterization of minor by-products was
prevented by their relatively low yields.
The structural integrity of the six analogs was confirmed
using 1H NMR and far-UV circular dichroism as illustrated in
supplemental Figs. S2 and S3. The CD spectra obtained for
prepared analogs are similar to the broadly -helical secondary
structure profile obtained for non-modified IGF-II. The pres-
ence of the expected tertiary structure was further confirmed
by 1D 1H (supplemental Fig. S2) NMR spectra, and each analog
compared well with the native IGF-II profile.
Receptor Binding—The binding affinities of the IGF-II ana-
logs toward human IR-A and IGF-1R together with binding
affinities of selected analogs to IR-B are summarized in Table 1
and Fig. 2. The corresponding binding curves are shown in
supplemental Figs. S4–S6.
IR-A Binding Affinities—All modifications led to a signifi-
cantly impaired IR-A binding, ranging from 4.2 to 1.1% of the
insulin affinity when compared with IGF-II (7.9%). The
[N29]IGF-II B-domain mutant gave a 2-fold reduction in IR-A
affinity, whereas the analogs with C-domain insertions exhibited
stronger negative effects. [R34_GS]IGF-II showed an almost
3-fold reduction in binding (2.8%), whereas [S39_PQ]IGF-II
showedan8-fold reduction.All of the analogsbearing thePro-Gln
motif were significantly less active (1.1–1.8%), and further combi-
nations did not appear to have any additive effect.
IGF-1R Binding Affinities—An insertion of IGF-I-like features,
S29N, Gly-Ser, Pro-Gln alone, or a combination of Gly-Ser and
Pro-Gln, within the IGF-II molecule led rather unexpectedly to a
moderate decrease of binding potency toward IGF-1R (Table 1
and Fig. 2). However, the Pro-Gln insertion combined with the
S29Nmutation resulted in an increase in binding potency to that
of 18.8% to IGF-I in comparison with IGF-II (10.9%). In contrast,
this effectwas negatedwhen the S29Nmutationwas combinedwith
both insertions.
IR-B Binding Affinities—Both reference molecules, commer-
cial IGF-II and our recombinant IGF-II, show similar binding
potency for IR-B compared with IGF-I (1.9 and 1.5% of human
insulin, respectively;40 nM; Table 1). The IR-B binding affin-
ity of [N29]IGF-II dropped to almost one-third of the potency
obtained for IGF-II (0.6%; 108 nM).
Structural Characterization of IGF-II Analogs by NMR
Spectroscopy—We selected two IGF-II analogs with the most
pronounced impact on receptor binding [S39_PQ]IGF-II (with
lowest IR-A and IGF-1R binding) and [N29,S39_PQ]IGF-II
(with decreased IR-A and enhanced IGF-1R binding) (Table 1
and Fig. 2) for NMR structural characterization to understand
the molecular basis of Pro-Gln and S29N modifications.
Undesirable dynamic and aggregation behavior of IGF-II
severely affects the quality of NMR spectra of this protein and
would prevent the accurate structural determination required
for a detailed comparison between these analogs. Previously, it
has been shown that upon binding to an engineered high affin-
ity Domain 11 (D11) of the IGF-2R the spectral properties of
IGF-II improve dramatically (65). The fact that the IGF-IImod-
ifications reported here are distributed on the opposing face to
theD11 binding site allowed this system to be utilized for struc-
tural studies of the B- and C-domains. As expected, the binding
of either 15N- or 13C/15N-labeled IGF-II analogs to unlabeled
D11 led to a significant line narrowing of the NMR signals as
illustrated in supplemental Fig. S7 despite the more than a
Receptor Specificity of IGF-II Analogs
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2-fold increase in the total molecular mass of the system. First,
we determined the structure of the D11-bound unmodified
IGF-II that was utilized in the structural analysis of IGF-II ana-
logs. As expected, it is highly similar to the previously published
structure (65) with some regions being more resolved, espe-
cially around the sites modified in the analogs, reflecting the
substantially higher number of experimental restraints (1039
versus 764 unambiguous NOE restraints (supplemental Table
S1 and Ref. 65)). Next, we verified that binding to D11 did not
significantly affect the IGF-II C-domain and C-terminal
portion of the B-domain by comparison of assigned 2D
1H-15N HSQC spectra of free and D11-bound [S39_PQ]IGF-II
(supplemental Fig. S8). Although significant chemical shift per-
turbations were observed over the A-domain and the first 75%
of the B-domain, the regions containing the mutations showed
very small or negligible chemical shift perturbations.
Both analogs, [S39_PQ]IGF-II and [N29,S39_PQ]IGF-II,
preserved their overall structural organization with the three
highly conserved -helices further stabilized by three disulfide
bonds. As expected, the D11 binding interface on the IGF-II
analogs was not perturbed by the modifications, and structural
changes were restricted to the modification sites (Fig. 3). In
both analogs, theC-domain insertion led to a significant change
in the conformational space sampled by this region of the pro-
tein compared with unmodified IGF-II with the main differ-
ences residing between residues 29 and 42. Detailed analysis
(Fig. 4) revealed that the insertion of Pro-Gln after Ser39 led to
increased conformational freedom within the C-loops of both
analogs that generated a rearrangement stabilized by several
new packing interactions in the remote part of the C-domain.
In the native IGF-II sequence, Tyr27 points away from the
C-loop and forms hydrophobic contacts with Ala61, whereas
the C-loop is unrestrained by additional contacts to the other
parts of IGF-II (Fig. 4A). By contrast, the aromatic ring of Tyr27
forms contacts to the methyl group of Ala32 in [S39_PQ]IGF-II
(Fig. 4B) and Arg30 and Pro31 in [N29,S39_PQ]IGF-II (Fig. 4C).
Arg30 is no longer unrestrained in these analogs and interactswith
the aromatic ring of Tyr61 (Tyr59 in unmodified IGF-II) via a cat-
ion- interaction. These new hydrophobic contacts lead to the
formation of a better defined C-loop that bends around the bulky
side chainsofTyr27 andTyr61 of bothC-domain-modified analogs
(Fig. 4, B and C). In comparison with unmodified IGF-II, the
extended C-domain in both analogs is spatially constrained and
bent toward the triad of aromatic residues at theC terminus of the
B-domain (Phe26, Tyr27, and Phe28). Ser29 in IGF-II (Fig. 4A) is
located at the hinge of the semiflexible loop with no significant
contacts to neighboring residues. The Pro-Gln extension in
[S39_PQ]IGF-II led to the repositioningofSer29 incloseproximity
to Tyr27, although there are no observed NOE contacts between
Ser29 protons and Tyr27 or surrounding residues. However, the
hydroxyl proton from its side chain may be involved in hydrogen
bonds, e.g. with the backbone carboxyl groups either from Pro31
(2.8 Å in half of the structures), which is closer in the extended
loop, or from Arg42 (2.8 Å in a quarter of the structures) at the
opposite sideof the loop (Figs. 4Band5).ThemodificationofSer29
toAsn29 in [N29,S39_PQ]IGF-II led toa lossof thishydrogenbond
and a subtle conformational rearrangement of the C-loop back-
bone. Inaddition, theAsn29 sidechain ispointingoutof theC-loopTA
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and is fully solvent-exposed with NOE contacts between the NH2
group from the Asn29 side chain and H2 from Phe28, perhaps
further stabilizing the cluster of contacts between the C-domain
and aromatic triad that in turnmight stabilize the additional inter-
actions seen between Tyr27 and Arg30/Pro31 (Fig. 4C) that were
not observed for the [S39_PQ]IGF-II analog.
Discussion
IGF-II is capable of binding to both IR-A and IGF-1R with
single digit nanomolar affinity (Kd 3 nM; Table 1) and to IR-B
with lower affinity (40 nM; Table 1). Although the binding
affinities of the “parent” ligands, insulin and IGF-I, toward their
cognate receptors are in the subnanomolar range (Table 1),
IGF-II can still effectively signal through both IR-A and IGF-1R
receptors or their hybrid forms in vivo (66, 67), which may
trigger unfavorable biological responses. The knowledge about
structural elements within these hormones responsible for dif-
ferential binding specificity to each receptor could open a new
path to the development of receptor-selective IGF and insulin
analogs with potential medical applications. The analogs pre-
FIGURE 2. Summary of receptor binding affinities. Shown is a bar plot representation of relative binding affinities (from Table 1) of native hormones and
IGF-II analogs prepared in this work for human IR-A (A), IGF-1R (B), and IR-B (C). Error bars represent S.D.
FIGURE 3. Solution structures of [S39_PQ]IGF-II (orange) and [N29,S39_PQ]IGF-II (purple) compared with non-modified IGF-II (gray). A and B show
representative structures of the Domain 11-bound IGF-II analogs, and C and D show sets of 20 converged structures bound to D11 (white). The insertion of
Pro-Gln in the C-domain after position 39 led to a significant structural rearrangement of the semiflexible loop.
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pared and structurally characterized in this workwere designed
to investigate the effects of introducing unique IGF-Imotifs (i.e.
Asn26, Gly30-Ser31, and Pro35-Gln36; Fig. 1) to IGF-II on recep-
tor binding behavior.We hypothesized that suchmodifications
may negatively affect the hormone’s binding potency toward
IR-A while enhancing the binding affinity for IGF-1R. More-
over, there are no reported analogs with the mutation of Ser29
in IGF-II, and there are only a few studies regarding alterations
in the C-domain (57, 59).
The development of an efficient protocol for IGF-II produc-
tion was a key step in being able to reliably prepare the IGF-II
analogs. The total chemical synthesis of IGF-II is extremely
difficult and time-consuming due to the length and unfavorable
composition of the IGF-II sequence (68). The most frequently
used recombinant approach, analogous to the production of
IGF-I (69, 70), is based on preparation of a fusion comprising
porcine growth hormone N-terminal residues 1–11 (plus
N-terminal Met), a subtilisin-specific cleavage sequence (Val-
Asn-Phe-Ala-His-Tyr2), and human IGF-II (71). However,
specifically mutated subtilisin (H64A) used for the procedure is
no longer commercially available. We therefore chose an alter-
native approach that includes an “on-column” refolding step of
denatured IGF-II in a fusion with His6-tagged GB1 protein (63,
64). Subsequent cleavage of the fusion protein in a redox envi-
FIGURE 4. Structural impact of the IGF-II modifications.Non-modified IGF-II (A; gray) is comparedwith [S39_PQ]IGF-II (B; orange) and [N29,S39_PQ]IGF-II (C;
purple), revealing different spatial orientation of highlighted residues. In particular, the rearrangement of the C-domain is driven by repositioning of Ala32
toward Tyr27 and Arg30 toward Tyr61 (Tyr59 in non-modified IGF-II) supported by additional contacts within this area.
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ronment and RP-HPLC purification yields IGF-II with only a
single additional glycine residue at the N terminus. This
improves on the recently reported recombinant method that
leaves three surplus N-terminal amino acids (glycine, alanine,
and methionine) (65, 72) and therefore reduces uncertainty in
interpreting structure and function of this protein in biological
assays.
The binding affinities of recombinantly produced IGF-II
toward IR-A, IR-B, and IGF-1R correlate with the values
obtained for commercial IGF-II (Table 1 and Fig. 2). These
comparable binding characteristics confirmed the correct
disulfide pairing as misfolded IGFs do not bind to IGF-1R or
IR-Awith ameasurable affinity (27, 73, 74). Thismethod there-
fore leads to a rapid and cost-effective preparation of authentic
IGF-II, providing us and others with an essential tool for study-
ing IGF-II-related structure and function.
Our initial goal to reduce IR-A affinity of IGF-II was success-
ful as all six IGF-II analogs showed reduced IR-Abinding (Table
1) with four of these showing low affinity similar to IGF-I. The
most significant was [S39_PQ]IGF-II with an 7–8-fold
reduction in affinity compared with IGF-II. Interestingly, this
reduction was greater than the effect of swapping the entire
IGF-II C-domain for IGF-I C-domain (3.7-fold) (57). Our data
and data of others (57, 59) suggest that there are two main
factors affecting the binding potency of IGF-II to IR-A. First, a
longer C-domain may introduce structural restrictions during
binding to the insulin receptor. This is in agreement with the
finding that IGF-I analogs with a shorter C-domain exhibit
enhanced binding affinity to IR-A (75). The second factor
relates to specific C-domain amino acids (e.g. Pro39 in IGF-I),
whichmay affect the structure of the C-domainmain chain and
therefore binding to IR-A.
Although we only tested a single analog for binding to IR-B,
the 2-fold reduction in binding observed for [N29]IGF-II sug-
gests a similar sensitivity to changes in the C-domain (Table 1).
Hence, we have not further pursued testing IR-B affinities of
analogs and we focused on binding to IGF-1R.
The combination of the Pro-Gln insertion with S29N muta-
tion in [N29,S39_PQ]IGF-II (Table 1 and Fig. 2) led to an analog
exhibiting higher binding affinity to IGF-1R compared with
native IGF-II. Our data suggest that the IGF-II specificity
toward IGF-1R is determined by the amino acid composition of
the C-domain rather than its length as demonstrated by the
relatively lower binding affinity of the [R34_GS,S39_PQ]IGF-II
analog. The selectedmutations do not completely recover IGF-
I-like binding to IGF-1R and cannot counterbalance the
absence of other important IGF-I determinants (e.g. IGF-I
Tyr31 (76–78)). Nonetheless, the almost doubling in IGF-1R
binding affinity of [N29,S39_PQ]IGF-II analog togetherwith its
markedly lowered affinity for IR-A resulted in almost 10-fold
enhanced IGF-1R/IR-A binding specificity in comparison with
IGF-II.
The comparison of D11-bound structures of IGF-II,
[S39_PQ]IGF-II and [N29,S39_PQ]IGF-II, revealed that both
analogs differ from IGF-II in the orientation and structuring of
their C-loops (Figs. 3 and 4). The significant and similar dis-
placement of the C-loops in both [S39_PQ]IGF-II and
[N29,S39_PQ]IGF-II together with their more open C-loop
conformations can be attributed to the effect of their PQ
inserts. Moreover, the C-loop loops back to generate a turn
stabilized by contacts between Tyr27 and Ala32 and a hydrogen
bond between Ser29 and Pro31 or Arg42 in [S39_PQ]IGF-II
(Figs. 4B and 5). The absence of this hydrogen bond due to the
S29Nmutation in [N29,S39_PQ]IGF-II might be compensated
for by Pro31 packing against Tyr27 (Fig. 4C). A comparable
decrease in IR-A binding affinities of [S39_PQ]IGF-II and
[N29,S39_PQ]IGF-II in comparison with IGF-II indicates it is
caused mainly by their similarly altered C-loop structures
rather than S29N mutation, which is well tolerated by IR-A.
In the crystal structure of human IGF-I (Protein Data Bank
code 1GZR) (29), the Asn26 side chain is solvent-exposed at the
interface of the B- and C-domains with the Asn26 presenting
a potential polar hot spot. An equivalent Asn29 in
[N29,S39_PQ]IGF-II is in a similar position but is less exposed
due to a partial overlap by the rearranged C-loop (Fig. 6A).
Asn26 is at the C terminus of the IGF-I B-domain, which is
structurally altered upon binding to IGF-1R or IR (54) (Fig. 6,
IGF-I receptor-bound structures in cyan). Analogous structural
events are observed upon insulin binding to IR (50, 53), and it
can be expected that receptor-driven activation of IGF-II is
similar. In the Menting et al. (54) structure (Protein Data Bank
code 4XSS), Asn26 is the last IGF-I B-domain residue resolved
in the complex with the hybrid IGF-IR/IR where it has been
captured in the binding site formed from the IGF-IR -CT and
IR L1 domains (Fig. 6B). However, the structure of the complex
did not reveal any specific contacts between IGF-I Asn26 and IR
L1 domain or IGF-IR -CT. However, it cannot be ruled
out that Ser29 within the IGF-II molecule (or Asn29 in
FIGURE 5. The formation of stabilizing hydrogen bond in [S39_PQ]IGF-II. The hydroxyl proton from the Ser29 side chain is stabilizing the C-loop via a
hydrogen bond to the backbone carboxyl groups either from Pro31 or Arg42.
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[N29,S39_PQ]IGF-II) may be involved in direct contacts to
IGF-1R, and this hypothesis could be supported by a positive
effect of S29N mutation on IGF-1R binding affinity of
[N29,S39_PQ]IGF-II. Hence, Ser29may represent an important
site for engineering of the IGF-1R binding specificity in IGF-II
analogs.
Concluding Remarks
We have developed a straightforward protocol for the pro-
duction of recombinant IGF-II with an additional glycine at the
N terminus. We prepared six IGF-II analogs with IGF-I-like
mutations. All these mutants have markedly reduced affinity
for IR-A, especially those analogswith Pro-Gln insertions in the
C-domain.Moreover, one of the analogs, [N29,S39_PQ]IGF-II,
shows the enhanced binding affinity for IGF-1R in comparison
with IGF-II due to the synergistic effect of Pro-Gln insertion
and S29Npointmutation. Consequently, this analog has almost
10-fold enhanced IGF-1R/IR-A binding selectivity in compari-
son with IGF-II. Structural characterization of selected analogs
revealed that the conformational rearrangement of the C-loop
induced by insertion of two residues from IGF-I ismanifested in
the reduced affinity for IR-A. A combination of the effect of this
insertion with an additional IGF-I like substitution, S29N,
driving the additional subtle rearrangement of the C-loop
forms a structural basis for the increased binding affinity of
[N29,S39_PQ]IGF-II for IGF-1R. To our knowledge, the
research reported here is a unique example of the determina-
tion of 3D structures of IGF-II analogs with modifications that
have an impact on receptor binding affinities. Identification of
structural determinants in IGFs and insulin that are responsible
for specific binding to their cognate receptors is important for
designing new, more specific hormone analogs with potential
therapeutic applications.
Experimental Procedures
Recombinant Expression of IGF-II Analogs
The human IGF-II sequence was cloned into a modified
pRSFDuet-1 expression vector fused with an N-terminal His6
tag, GB1 protein, and TEV protease cleavage site (Glu-Asn-
Leu-Tyr-Phe-Gln2Gly). An additional N-terminal Gly (1)
was incorporated to facilitate TEV cleavage. Mutation S29N,
Gly-Ser insertion following Arg34, Pro-Gln insertion following
Ser39, and a combination of both insertions were obtained by
site-directed mutagenesis (QuikChange kit, Agilent Technolo-
gies) performed with appropriate mutagenic primers of the
IGF-II sequence subcloned into the pBluescript vector. After
sequence verification, themutant fragments were reintroduced
into the full-length IGF-II in the expression vector. Constructs
were transformed into E. coli BL21(DE3) and cultivated using
LB medium or minimal medium containing [15N]ammonium
sulfate and D-[13C]glucose. The bacterial culture was grown at
37 °C to an optical density (550 nm) of1, induced with 1 mM
isopropyl -D-1-thiogalactopyranoside, and further cultured
for 4–5 h. Cells were harvested by centrifugation for 20 min at
4,000 g, and cell pellets were stored at20 °C prior to further
processing.
Isolation of Inclusion Bodies
Cells pellets were resuspended in lysis buffer (50 mM Tris-
HCl, pH 8.0, 50 mM NaCl, 5 mM EDTA, 50 M PMSF) using 10
ml of buffer/1 g of biomass and homogenized by three passes
through an Avestin EmulsiFlex-C3 apparatus at 4 °C and
homogenization pressure of 1,200 megapascals. Inclusion bod-
ies from the cell lysate were obtained by centrifugation at
20,000  g at 4 °C for 20 min and further washed as a suspen-
sion in a wash buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5
mM EDTA) with 0.1% (v/v) Triton X-100, sonicated in an ice
bath, and centrifuged (20,000  g, 4 °C, 20 min). The wash
procedure was repeated in the absence of 0.1% (v/v) Triton
X-100, and wet paste consisting of inclusion bodies was stored
at20 °C.
Purification of IGF-II and Analogs
The inclusion bodies were resuspended in a minimum vol-
ume (2ml/g of wet paste) of 50mMTris-HCl, pH 8.0 buffer with
300 mM NaCl and sufficient -mercaptoethanol to yield a final
FIGURE 6. A superposition of free or hybrid IR/IGF-1R fragment-bound forms of IGF-I with [N29,S39_PQ]IGF-II. A, an overlay of the backbone of
free human IGF-I (Protein Data Bank code 1GZR; in blue) with [N29,S39_PQ]IGF-II (in purple) and IGF-I from a complex with the L1 domain from IR and
IGF-1R -CT peptide (Protein Data Bank code 4XSS; in cyan). The positions of Asn26 in IGF-I and Asn29 in IGF-II side chains are highlighted. B, the crystal
structure (Protein Data Bank code 4XSS) of IGF-I (in cyan) in a complex with IR L1 domain (in white) and IGF-1R -CT peptide (in green) overlaid with
[N29,S39_PQ]IGF-II in purple.
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concentration of 0.02% (v/v) after the following dilution step.
The suspensionwas gently diluted into 50mMTris-HCl, pH 8.0
buffer with 300 mM NaCl and 8 M urea to a final concentration
of 1 g (wet weight of inclusion bodies)/50 ml and incubated
for 2–3 h at room temperature with moderate stirring. The
solution of the denatured fusion protein was then loaded onto
an equilibrated HisTrap HP (5 ml) column connected to an
ÄKTA FPLC system (GE Healthcare), and after washing with
50 mM Tris-HCl, pH 8.0 buffer with 300 mMNaCl, the retained
protein was eluted using a 0–500 mM imidazole gradient in 50
mM Tris-HCl, pH 8.0 buffer with 300 mM NaCl within 10 col-
umn volumes. The presence of the fusion protein in collected
fractions was verified by SDS-PAGE and anti-His6 Western
blotting, and the pooled fractions were dialyzed at 6 °C against
50 mM Tris-HCl, pH 8.0, 300 mMNaCl. The fusion partner was
subsequently cleaved by an overnight TEV digestion in the
presence of reduced and oxidized glutathione (1.5mMGSHand
0.15 mM GSSG) at room temperature. Cleaved IGF-II was sep-
arated from the fusion protein by a gravity flow nickel chelating
chromatography (HIS-Select Nickel Affinity Gel, Sigma-Al-
drich) and further desalted on a Chromabond C4 column
(Macherey-Nagel) using 80%CH3CN (v/v) with 0.1%TFA (v/v)
for elution. The collected protein fraction was lyophilized;
resuspended in 7% (v/v) acetic acid, 27% (v/v) CH3CN, 0.03%
TFA (v/v); and purified on a semipreparative RP-HPLC column
(Vydac 214TP510-C4, 250 10mm) using aCH3CN/H2Ogradi-
ent supplemented with 0.1% TFA (v/v). The separated fractions
were lyophilized, the purity of products was analyzed by analytical
RP-HPLC, and the identity of the products was verified by high
resolution electrospray ionization mass spectrometry (LTQ
Orbitrap XL, Thermo Fisher Scientific,Waltham,MA).
NMR Spectroscopy
All NMR data for free IGF-II and analogs were acquired at
25 °C using 600- and 850-MHz Bruker Avance II spectrome-
ters, both ofwhichwere equippedwith 1H/13C/15N cryoprobes.
To confirm the correct fold of IGF-II analogs, 1D 1H spectra
(unlabeled samples) and 2D 1H-15N HSQC spectra were
acquired. The NMR spectra were collected using 350-l sam-
ples of protein (75–380 M) dissolved in 50 mM d4-acetic acid
(pH 3.0), 5% D2O (v/v), 0.01% (w/v) NaN3. Data for IGF-II and
analogs bound to a high affinity Domain 11 variant of IGF-2R
(D11) (65, 72) were acquired from 350-l samples of 200–400
M IGF-IID11 complex in acetate buffer (20mM d4-acetic acid,
pH 4.2, 5% D2O (v/v), 0.01% (w/v) NaN3) at 35 °C.
To determine the structure of either free or bound IGF-IIs, a
series of double and triple resonance spectra (79, 80) were
recorded on 13C/15N uniformly labeled IGF-II or analogs to
determine essentially complete sequence-specific resonance
backbone and side chain assignments. Constraints for 1H-1H
distances were derived from 3D 15N-1H NOESY-HSQC and
13C-1H NOESY-HMQC, which were acquired using an NOE
mixing time of 100 ms.
The family of converged structures was initially calculated
using Cyana 2.1 (81). The combined automated NOE assign-
ment and structure determination protocol was used to auto-
matically assign the NOE cross-peaks identified in NOESY
spectra and to produce preliminary structures. In addition,
backbone torsion angle constraints, generated from assigned
chemical shifts using the program TALOS	 (82), were
included in the calculations. Subsequently, five cycles of simu-
lated annealing combined with redundant dihedral angle con-
straints were used to produce sets of converged structures with
no significant restraint violations (distance and van der Waals
violations0.2 Å and dihedral angle constraint violation5°),
which were further refined in explicit solvent using YASARA
software with the YASARA force field (83). The structures with
the lowest total energy were selected. Analysis of the family of
structures obtained was carried out using the Protein Structure
Validation Software suite (Northeast Structural Genomics con-
sortium) and MOLMOL (84). The statistics for the resulting
structures are summarized in supplemental Table S1.
Circular Dichroism
CD spectraweremeasured in a quartz cuvettewith an optical
path length of 0.5 mm (Starna Cells) using a J-815 spectropola-
rimeter (Jasco, Japan) at room temperature. The far- and
near-UV CD spectra were used to identify changes in protein
secondary and tertiary structures. The spectral regions were
200–300 nm. The final spectra were obtained as an average of
five accumulations. The spectra were corrected for the baseline
by subtracting the spectra of the corresponding polypeptide-
free solution. Analogs or IGF-II was dissolved and measured in
5% aqueous acetic acid (0.33 mg/ml; 45 M).
Receptor Binding Studies
Commercial human insulin and IGF-II were provided by
Sigma-Aldrich, and human IGF-I was provided by Tercica.
Human IM-9 Lymphocytes (Human IR-A Isoform)
Receptor binding studies with the insulin receptor in mem-
branes of human IM-9 lymphocytes (containing only human
IR-A isoform) were carried out, andKd values were determined
according to the procedure described recently (85). Binding
datawere analyzed by Excel algorithms especially developed for
the IM-9 cell system in the laboratory of Prof. Pierre De Meyts
(developed by A. V. Groth and R. M. Shymko, Hagedorn
Research Institute, Denmark; a kind gift of P. DeMeyts) using a
method of non-linear regression and a one-site fitting program
and taking into account potential depletion of free ligand. Each
binding curve was determined in duplicate, and the final disso-
ciation constant (Kd) of an analog was calculated from at least
three (n  3) independently determined binding curves. The
dissociation constant of human 125I-insulin was set to 0.3 nM.
Mouse Embryonic Fibroblasts
Human IR-B Isoform—Receptor binding studies with the
insulin receptor in membranes of mouse embryonic fibroblasts
derived from IGF-I receptor knock-out mice that solely
expressed the human IR-B isoform were performed as described
in detail previously (86, 87). Binding data were analyzed, and
the dissociation constant (Kd) was determined with GraphPad
Prism 5 software using amethod of non-linear regression and a
one-site fitting program and taking into account potential
depletion of free ligand. Kd values of analogs were determined
and calculated by the same procedure as for IR-A.
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Human IGF-1R—Receptor binding studies with the IGF-I
receptor inmembranes ofmouse embryonic fibroblasts derived
from IGF-1R knock-out mice and transfected with human
IGF-1R were performed as described previously (86, 87). Bind-
ing data were analyzed, and the dissociation constants were
determined and calculated by the samemethod as for IR-B. The
dissociation constant of human 125I-IGF-I was set to 0.2 nM.
Mouse embryonic fibroblasts expressing human IR-B or
IGF-1R were a kind gift from Prof. Antonino Belfiore (Univer-
sity of Magna Grecia, Catanzaro, Italy) and Prof. Renato
Baserga (Thomas Jefferson University, Philadelphia, PA). Here
we should note that the use of bovine serum albumin (e.g.
Sigma-Aldrich A6003) void of “IGF-binding-like” proteins,
which interfere with these binding assays, is essential for the
preparation of the binding buffer (88).
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Figure S1. Purification procedure for IGF-II analogs. A. The elution profile from purification 
of denatured IGF-II in fusion with GB1 protein by IMAC. The material eluted in two major 
fractions (1-2 and 4-5) at two different imidazole concentrations. SDS-PAGE analysis of collected 
fractions (1-5) under reducing (B) and non-reducing (C) conditions revealing the presence of two 
monomeric isoforms (folded and misfolded) eluting at lower concentration of imidazole (150 mM) 
and multimeric aggregates eluting at higher imidazole concentration (400 mM). M, molecular 
weight standard; L, sample load; FT, flow through; W1 and W2, wash; 1-5, eluted fractions. Panel 
D shows reducing SDS-PAGE of the fusion partner cleavage by TEV protease. A1, monomeric 
fractions before TEV addition; A2, monomeric fractions after 24hrs of TEV digestion; B1, 
multimeric fraction before TEV addition; B2, multimeric fractions after 24hrs of TEV digestion; 
M, molecular weight standards. Panel E shows reducing SDS-PAGE of cleaved sample after nickel 
chelating chromatography. The cleaved IGF-II is present in FT and W fraction. L, sample load, FT, 
flow through; W, wash; E, elution; M, molecular weight standard. Panel F shows the final RP-
HPLC purification of IGF-II separating forms with differently linked disulfide bonds. 
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Figure S2. 1H NMR spectra of IGF-II analogues. (A) IGF-II, (B) misfolded IGF-II, (C) [N29]-
IGF-II, (D) [R34_GS]-IGF-II, (E) [S39_PQ]-IGF-II, (F) [R34_GS,S39_PQ]-IGF-II, (G) [N29, 
S39_PQ]-IGF-II,  (H) [N29, R34_GS, S39_PQ]-IGF-II. The difference between correctly folded 
(A) and misfolded (B) IGF-II spectra was used for verification of correct protein folding of the 
IGF-II analogs (C-H). In particular, the presence of dispersed aromatic proton signals at 6.5 ppm 
and upfield shifted methyl signals between 0.5 and -0.2 ppm could be utilized to fingerprint 
correctly folded IGF-II. 
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Figure S3. Far UV circular dichroism spectra of IGF-I and studied IGF-II analogs 
normalized to 207 nm. The curve profiles suggest highly similar presence of the α-helical 
secondary structure elements in the studied IGF-II analogs.  
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Figure S4. Inhibition of binding of human [125I]-insulin to IR-A in membranes of IM-9 cells 
by human insulin, IGF-I, IGF-II and IGF-II analogs.  
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Figure S5. Inhibition of binding of human [125I]-IGF-I to IGF-1R in membranes of mouse 
fibroblasts by human insulin, IGF-I, IGF-II and IGF-II analogs.   
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Figure S6. Inhibition of binding of human [125I]-insulin to IR-B in membranes of mouse 
fibroblasts by human insulin, IGF-I, IGF-II and [N29]-IGF-II analog. 
 
 
 
Figure S7. Significant narrowing of IGF-II signals in 1H/15N HSQC spectrum upon binding 
to IGF-2R Domain 11. A spectrum of free 15N labelled IGF-II is shown on the left panel. Obtained 
signals do not correspond to the protein mass of 7.5 kDa. The right panel illustrates the signal 
narrowing observed for IGF-II bound to Domain 11. 
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Figure S8. The C-domain of IGF-II is not affected by D11 binding. 
(A) An overlay of 1H/15N HSQC spectra obtained for the free (red) and D11-bound [S39_PQ]-IGF-
II (black). (B) Values of combined chemical shift changes calculated from the changes of backbone 
amide signal positions. The major differences upon binding to D11 are distributed across the D11 
binding interface, while the signals of the C-domain backbone amides bearing the modifications 
remain relatively unaffected by the D11 binding.  
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Table S1. NMR restraints and structural statistics 
 IGF-II [S39_PQ]-IGF-II 
[N29, S39_PQ]- 
IGF-II 
Non-redundant distance and angle 
constrains 
   
Total number of NOE constraints 1039 1116 1395 
Short-range NOEs    
Intra-residue (i = j) 301 315 341 
Sequential (| i - j | = 1) 321 356 406 
Medium-range NOEs (1 < | i - j | < 5) 160 185 281 
Long-range NOEs (| i - j | ≥ 5) 254 257 364 
Torsion angles 46 46 46 
Hydrogen bond restrains - - - 
Total number of restricting constraints 1085 1162 1441 
Total restricting constraints per 
restrained residue 
16.2 16.8 20.9 
Residual constraint violations    
Distance violations per structure    
0.1 – 0.2 Å 5.05 5.85 9 
0.2 – 0.5 Å 2.15 2.3 2.6 
> 0.5 Å 0 0 0 
r.m.s. of distance violation per 
constraint 
0.02 Å 0.02 Å 0.02 Å 
Maximum distance violation 0.45 Å 0.48 Å 0.48 Å 
Dihedral angle violations per structure    
1 – 10 ° 1.3 1.2 1.7 
> 10 ° 0 0 0 
r.m.s. of dihedral violations per 
constraint 
0.68 ° 0.71 ° 0.75 ° 
Maximum dihedral angle violation 5.00 ° 5.00 ° 5.00 ° 
Ramachandran plot summary from 
Procheck 
   
 Most favoured regions 94.8% 92.2% 85.9% 
 Additionally allowed regions 5.2% 7.8% 13.8% 
 Generously allowed regions 0.0% 0.0% 0.1% 
 Disallowed regions 0.0% 0.0% 0.1% 
r.m.s.d. to the mean structure ordered1 all ordered1 all ordered1 all 
All backbone atoms 0.4 Å 2.9 Å 1.1 Å 2.2 Å 1.0 Å 1.9 Å 
All heavy atoms 1.0 Å 3.6 Å 1.7 Å 2.9 Å 1.4 Å 2.5 Å 
1 Residues with sum of phi and psi order parameters > 1.8 
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